Personalized medicine has the potential to revolutionize healthcare by enabling more effective and precise treatments for a wide range of conditions and diseases. 3D printing can allow flexible, on-demand dosing at point-of-care locations by tailoring the shape, size, dose and dissolution profile of the 3D printed tablets. 3D printing via direct extrusion followed by additive manufacturing (DEAM) will be applied in the current project to target a broader formulation window compared to conventional filament-based 3D printing, including formulations with unsuitable mechanical filament properties as well as drug substances prone to thermal degradation. This project will evaluate the potential of DEAM for 3D printing of tablets using high drug-loaded pellets, granules and powders as feedstock. The ideal feedstock type and characteristics as well as critical process parameters will be defined. Moreover, the relationship between the dose, in vitro drug release and tablet design will be examined.